欧洲泌尿外科学会2021版性健康与生殖健康指南:男性性功能障碍
该指南基于截至2021年1月的文献更新,涵盖迟发性性腺功能减退、勃起功能障碍、早泄和血精的诊断与治疗推荐,强调个体化治疗和多学科管理。
要点
- 迟发性性腺功能减退需综合低睾酮水平和相关症状进行诊断与治疗。
- 勃起功能障碍治疗采用新决策算法以个体化定制方案。
- 早泄按国际性医学学会定义分型, lifelong PE一线治疗为药物,获得性PE先治病因。
核心结论
- 2021版指南总结了男性性腺功能减退和性功能障碍诊断与治疗的最新证据,推荐用于临床实践。
研究设计与样本
- 基于截至2021年1月的文献综述更新,推荐强度基于系统评价或专家共识。
主要发现
- 迟发性性腺功能减退是老年男性低循环睾酮与特定症状结合的临床状况。
- 勃起功能障碍定义为持续无法达到或维持足以满意性行为的勃起。
- 早泄采用国际性医学学会定义,分型后讨论患者期望并选择治疗。
- 血精管理主要目标是排除恶性肿瘤并治疗其他 underlying cause。
关键数值与推荐
- lifelong PE一线治疗为药物治疗,获得性PE初始目标为治疗 underlying cause。
- 血精管理需排除恶性肿瘤。
临床怎么用
- 临床中应按照指南进行综合诊断评估,并与患者共同决策个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The present summary of the European Association of Urology (EAU) guidelines is based on the latest guidelines on male sexual health published in March 2021, with a last comprehensive update in January 2021. OBJECTIVE: To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health. EVIDENCE ACQUISITION: A literature review was performed up to January 2021. The guidelines were updated, and a strength rating for each recommendation was included based on either a systematic review of the evidence or a consensus opinion from the expert panel. EVIDENCE SYNTHESIS: Late-onset hypogonadism is a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. A comprehensive diagnostic and therapeutic work-up, along with screening recommendations and contraindications, is provided. Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Along with a detailed basic and advanced diagnostic approach, a novel decision-making algorithm for treating ED in order to better tailor therapy to individual patients is provided. The EAU guidelines have adopted the definition of premature ejaculation (PE), which has been developed by the International Society for Sexual Medicine. After the subtype of PE has been defined, patient's expectations should be discussed thoroughly and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. Haemospermia is defined as the appearance of blood in the ejaculate. Several reasons of haemospermia have been acknowledged; the primary goal over the management work-up is to exclude malignant conditions and treat any other underlying cause. CONCLUSIONS: The 2021 guidelines on sexual and reproductive health summarise the most recent findings, and advise in terms of diagnosis and treatment of male hypogonadism and sexual dysfunction for their use in clinical practice. These guidelines reflect the multidisciplinary nature of their management. PATIENT SUMMARY: Updated European Association of Urology guidelines on sexual and reproductive health are presented, addressing the diagnosis and treatment of the most prevalent conditions in men. Patients must be fully informed of all relevant diagnostic and therapeutic options and, together with their treating physicians, decide on optimal personalised management strategies.
引用
- Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur Urol. 2021. PMID: 34183196. doi:10.1016/j.eururo.2021.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。